{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T05:23:49Z","timestamp":1793856229806,"version":"4.6.1"},"reference-count":92,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Biliary tract malignancies, including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gallbladder cancer, represent a group of aggressive cancers with poor prognosis due to late-stage diagnosis, limited treatment options, and resistance to conventional therapies like chemotherapy and radiotherapy. These challenges emphasize the urgent need for innovative therapeutic approaches. In recent years, cell-based therapies have emerged as a promising avenue, offering potential solutions through immune modulation, genetic engineering, and targeted intervention in the tumor microenvironment. This Mini-review provides an overview of current advancements in cell-based therapies for biliary malignancies, encompassing immune cell-based strategies such as CAR-T cells, NK cells, dendritic cell vaccines, and tumor-infiltrating lymphocytes. We also examine strategies to overcome the immunosuppressive tumor microenvironment and discuss the integration of cell therapies into multimodal treatment regimens. By synthesizing preclinical and clinical findings, this review highlights key insights and future directions, aiming to assist researchers and clinicians in translating these approaches into effective treatments. The transformative potential of cell-based therapies discussed here makes this review a valuable resource for advancing biliary malignancy research and clinical applications.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1559465","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T11:00:37Z","timestamp":1739358037000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Advancing biliary tract malignancy treatment: emerging frontiers in cell-based therapies"],"prefix":"10.3389","volume":"16","author":[{"given":"Jianyang","family":"Ao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingtai","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary tract cancer","volume":"397","author":"Valle","year":"2021","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.09.004","article-title":"Rational development of combination therapies for biliary tract cancers","volume":"78","author":"Harding","year":"2023","journal-title":"J Hepatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41572-022-00398-y","article-title":"Gallbladder cancer","volume":"8","author":"Roa","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"B4","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1146\/annurev-med-042921-024707","article-title":"FGFR2 inhibition in cholangiocarcinoma","volume":"74","author":"Vogel","year":"2023","journal-title":"Annu Rev Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00544","article-title":"Comprehensive immunogenomic profiling of IDH1-\/2-altered cholangiocarcinoma","volume":"8","author":"Makawita","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.03.007","article-title":"Molecular targeted therapies: Ready for \u201cprime time\u201d in biliary tract cancer","volume":"73","author":"Lamarca","year":"2020","journal-title":"J Hepatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00171-0","article-title":"Current and emerging therapies for advanced biliary tract cancers","volume":"6","author":"Kam","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01808-x","article-title":"Treating biliary tract cancers: new targets and therapies","volume":"82","author":"Ho","year":"2022","journal-title":"Drugs"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.06.023","article-title":"Single-cell RNA-sequencing atlas reveals an MDK-dependent immunosuppressive environment in ErbB pathway-mutated gallbladder cancer","volume":"75","author":"Zhang","year":"2021","journal-title":"J Hepatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2023-331773","article-title":"Comprehensive single-cell analysis deciphered microenvironmental dynamics and immune regulator olfactomedin 4 in pathogenesis of gallbladder cancer","volume":"73","author":"He","year":"2024","journal-title":"Gut"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2023.11.001","article-title":"The state of cell and gene therapy in 2023","volume":"31","author":"Chancellor","year":"2023","journal-title":"Mol Ther"},{"key":"B13","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1126\/science.ads0252","article-title":"Cell and gene therapy accessibility","volume":"385","author":"Rouce","year":"2024","journal-title":"Science"},{"key":"B14","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1007\/s12029-024-01054-2","article-title":"CAR-T cell therapy in pancreatic and biliary tract cancers: an updated review of clinical trials","volume":"55","author":"Drougkas","year":"2024","journal-title":"J Gastrointest Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2023.09.021","article-title":"Arming CAR-T cells with cytokines and more: Innovations in the fourth-generation CAR-T development","volume":"31","author":"Tang","year":"2023","journal-title":"Mol Ther"},{"key":"B16","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","article-title":"Exploring the NK cell platform for cancer immunotherapy","volume":"18","author":"Myers","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/cr.2016.157","article-title":"Dendritic cell-based immunotherapy","volume":"27","author":"Sabado","year":"2017","journal-title":"Cell Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-00565-9","article-title":"Tumor-infiltrating lymphocytes in the immunotherapy era","volume":"18","author":"Paijens","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12943-022-01518-8","article-title":"Current applications and future perspective of CRISPR\/Cas9 gene editing in cancer","volume":"21","author":"Wang","year":"2022","journal-title":"Mol Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107753","article-title":"Tumor microenvironment as a therapeutic target in cancer","volume":"221","author":"Xiao","year":"2021","journal-title":"Pharmacol Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1189","article-title":"Periostin and mesothelin: Potential predictors of Malignant progression in intrahepatic cholangiocarcinoma","volume":"2","author":"Mandrekar","year":"2018","journal-title":"Hepatol Commun"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1131","article-title":"Overexpression of periostin and distinct mesothelin forms predict Malignant progression in a rat cholangiocarcinoma model","volume":"2","author":"Manzanares","year":"2018","journal-title":"Hepatol Commun"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-3841","article-title":"Mesothelin CAR T cells secreting anti-FAP\/anti-CD3 molecules efficiently target pancreatic adenocarcinoma and its stroma","volume":"30","author":"Wehrli","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-022-03238-w","article-title":"Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer","volume":"72","author":"Chen","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.186268","article-title":"Affinity-tuned mesothelin CAR T cells demonstrate enhanced targeting specificity and reduced off-tumor toxicity","volume":"9","author":"Yang","year":"2024","journal-title":"JCI Insight"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2023.2225291","article-title":"Preclinical evaluation of chimeric antigen receptor T cells targeting the carcinoembryonic antigen as a potential immunotherapy for gallbladder cancer","volume":"12","author":"Lopez","year":"2023","journal-title":"Oncoimmunology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.1038\/s41467-024-46654-5","article-title":"Targeting pathogenic CD8(+) tissue-resident T cells with chimeric antigen receptor therapy in murine autoimmune cholangitis","volume":"15","author":"Zhu","year":"2024","journal-title":"Nat Commun"},{"key":"B28","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1002\/cac2.12452","article-title":"Enhancement of CAR-T cell activity against cholangiocarcinoma by simultaneous knockdown of six inhibitory membrane proteins","volume":"43","author":"Qiao","year":"2023","journal-title":"Cancer Commun (Lond)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2021.1854724","article-title":"Experimental HER2- targeted therapies for biliary tract cancer","volume":"30","author":"Rizzo","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00336-3","article-title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study","volume":"22","author":"Javle","year":"2021","journal-title":"Lancet Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-0214","article-title":"Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial","volume":"18","author":"Ohba","year":"2022","journal-title":"Future Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00242-5","article-title":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study","volume":"24","author":"Harding","year":"2023","journal-title":"Lancet Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41435-024-00275-6","article-title":"HER2-targeting CAR-T cells show highly efficient anti-tumor activity against glioblastoma both in vitro and in vivo","volume":"25","author":"Li","year":"2024","journal-title":"Genes Immun"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2021.188549","article-title":"HER2-targeted therapies in gastric cancer","volume":"1876","author":"Zhu","year":"2021","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"819","DOI":"10.3390\/diagnostics14080819","article-title":"CAR-T cell therapy in ovarian cancer: where are we now","volume":"14","author":"Cutri-French","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.3390\/cancers15071987","article-title":"Emerging targeted therapies for HER2-positive breast cancer","volume":"15","author":"Mercogliano","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-024-00749-6","article-title":"Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial","volume":"5","author":"Hegde","year":"2024","journal-title":"Nat Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-024-01243-y","article-title":"Recent advances in immunotherapy for advanced biliary tract cancer","volume":"25","author":"Yue","year":"2024","journal-title":"Curr Treat Options Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1142690","article-title":"Revisiting targeted therapy and immunotherapy for advanced cholangiocarcinoma","volume":"14","author":"Du","year":"2023","journal-title":"Front Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.06.006","article-title":"Targeting PD-L1 in cholangiocarcinoma using nanovesicle-based immunotherapy","volume":"32","author":"Gondaliya","year":"2024","journal-title":"Mol Ther"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27840","article-title":"The biliary epithelium presents antigens to and activates natural killer T cells","volume":"62","author":"Schrumpf","year":"2015","journal-title":"Hepatology"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-023-00990-6","article-title":"Dendritic cell subsets in cancer immunity and tumor antigen sensing","volume":"20","author":"Del Prete","year":"2023","journal-title":"Cell Mol Immunol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"7211","DOI":"10.1038\/s41467-023-42881-4","article-title":"Immuno-metabolic dendritic cell vaccine signatures associate with overall survival in vaccinated melanoma patients","volume":"14","author":"Adamik","year":"2023","journal-title":"Nat Commun"},{"key":"B44","doi-asserted-by":"publisher","first-page":"3404","DOI":"10.3390\/cancers12113404","article-title":"A perspective on cell therapy and cancer vaccine in biliary tract cancers (BTCs)","volume":"12","author":"Han","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B45","doi-asserted-by":"publisher","first-page":"4265","DOI":"10.3390\/cancers15174265","article-title":"Advances in immunotherapeutics in pancreatic ductal adenocarcinoma","volume":"15","author":"Chouari","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.4161\/hv.23844","article-title":"Current status of immunotherapy for the treatment of biliary tract cancer","volume":"9","author":"Takahashi","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800588","article-title":"Immunohistochemical detection of WT1 protein in a variety of cancer cells","volume":"19","author":"Nakatsuka","year":"2006","journal-title":"Mod Pathol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v7.i11.338","article-title":"Immunotherapeutic approaches in biliary tract carcinoma: Current status and emerging strategies","volume":"7","author":"Marks","year":"2015","journal-title":"World J Gastrointest Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3892\/or_00000485","article-title":"Expression of MUC1, MUC2, MUC5AC and MUC6 in cholangiocarcinoma: prognostic impact","volume":"22","author":"Park","year":"2009","journal-title":"Oncol Rep"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110873","article-title":"Tumor-infiltrating lymphocytes: Warriors fight against tumors powerfully","volume":"132","author":"Lin","year":"2020","journal-title":"BioMed Pharmacother"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.05.043","article-title":"Multimodal single-cell profiling of intrahepatic cholangiocarcinoma defines hyperactivated Tregs as a potential therapeutic target","volume":"77","author":"Alvisi","year":"2022","journal-title":"J Hepatol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13046-022-02340-2","article-title":"The role of tumor-infiltrating lymphocytes in cholangiocarcinoma","volume":"41","author":"Liu","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-1265","article-title":"Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes as a potential biomarker for immune checkpoint inhibitors in patients with biliary tract cancer","volume":"30","author":"Bang","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0280348","article-title":"Tumor-infiltrating lymphocytes and macrophages as a significant prognostic factor in biliary tract cancer","volume":"18","author":"Tanaka","year":"2023","journal-title":"PloS One"},{"key":"B55","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1186\/s12885-018-4220-1","article-title":"Tumor-infiltrating mast cells predict prognosis and gemcitabine-based adjuvant chemotherapeutic benefit in biliary tract cancer patients","volume":"18","author":"Bo","year":"2018","journal-title":"BMC Cancer"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2020.704","article-title":"Spatial distribution and prognostic implications of tumor-infiltrating foxP3- CD4+ T cells in biliary tract cancer","volume":"53","author":"Kim","year":"2021","journal-title":"Cancer Res Treat"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.14264","article-title":"Preoperative neutrophil-to-lymphocyte ratio predicts tumor-infiltrating CD8(+) T cells in biliary tract cancer","volume":"40","author":"Tanaka","year":"2020","journal-title":"Anticancer Res"},{"key":"B58","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01462-y","article-title":"Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial","volume":"27","author":"Creelan","year":"2021","journal-title":"Nat Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.06.025","article-title":"Prognostic value of tumor-infiltrating lymphocytes (TILs) and their association with PD-L1 expression and DNA repair protein RAD51 in patients with resected non-small cell lung carcinoma","volume":"147","author":"Gachechiladze","year":"2020","journal-title":"Lung Cancer"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15602","article-title":"PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma","volume":"8","author":"Fontugne","year":"2017","journal-title":"Oncotarget"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1002\/jso.21376","article-title":"Interaction of B7-H1 on intrahepatic cholangiocarcinoma cells with PD-1 on tumor-infiltrating T cells as a mechanism of immune evasion","volume":"100","author":"Ye","year":"2009","journal-title":"J Surg Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-016-0474-1","article-title":"Clinical implications of cytotoxic T lymphocyte antigen-4 expression on tumor cells and tumor-infiltrating lymphocytes in extrahepatic bile duct cancer patients undergoing surgery plus adjuvant chemoradiotherapy","volume":"12","author":"Lim","year":"2017","journal-title":"Target Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25050","article-title":"Prognostic impact of programmed cell death ligand 1 (PD-L1) expression and its association with epithelial-mesenchymal transition in extrahepatic cholangiocarcinoma","volume":"9","author":"Ueno","year":"2018","journal-title":"Oncotarget"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3375","article-title":"Genomic spectra of biliary tract cancer","volume":"47","author":"Nakamura","year":"2015","journal-title":"Nat Genet"},{"key":"B66","doi-asserted-by":"publisher","first-page":"5486","DOI":"10.1038\/s41467-020-19314-7","article-title":"Synthesizing AND gate minigene circuits based on CRISPReader for identification of bladder cancer cells","volume":"11","author":"Liu","year":"2020","journal-title":"Nat Commun"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.09.049","article-title":"Synthetic RNA-based immunomodulatory gene circuits for cancer immunotherapy","volume":"171","author":"Nissim","year":"2017","journal-title":"Cell"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.01.011","article-title":"Precision tumor recognition by T cells with combinatorial antigen-sensing circuits","volume":"164","author":"Roybal","year":"2016","journal-title":"Cell"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc6270","article-title":"Precise T cell recognition programs designed by transcriptionally linking multiple receptors","volume":"370","author":"Williams","year":"2020","journal-title":"Science"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114145","article-title":"Precision off-the-shelf natural killer cell therapies for oncology with logic-gated gene circuits","volume":"43","author":"Frankel","year":"2024","journal-title":"Cell Rep"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-23-0486","article-title":"Reprogramming the intrahepatic cholangiocarcinoma immune microenvironment by chemotherapy and CTLA-4 blockade enhances anti-PD-1 therapy","volume":"12","author":"Chen","year":"2024","journal-title":"Cancer Immunol Res"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00048.2019","article-title":"Diversity and biology of cancer-associated fibroblasts","volume":"101","author":"Biffi","year":"2021","journal-title":"Physiol Rev"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00770-1","article-title":"Cholangiocarcinoma - novel biological insights and therapeutic strategies","volume":"20","author":"Ilyas","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/s41571-021-00546-5","article-title":"Clinical and therapeutic relevance of cancer-associated fibroblasts","volume":"18","author":"Chen","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000206","article-title":"Heterogeneity, crosstalk, and targeting of cancer-associated fibroblasts in cholangiocarcinoma","volume":"79","author":"Cantallops Vila","year":"2024","journal-title":"Hepatology"},{"key":"B76","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.ccell.2021.03.012","article-title":"Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations","volume":"39","author":"Affo","year":"2021","journal-title":"Cancer Cell"},{"key":"B77","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12943-022-01670-1","article-title":"Targeting the tumor stroma for cancer therapy","volume":"21","author":"Xu","year":"2022","journal-title":"Mol Cancer"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2024.114474","article-title":"Hyaluronidase overcomes the extracellular matrix barrier to enhance local drug delivery","volume":"203","author":"Zhao","year":"2024","journal-title":"Eur J Pharm Biopharm"},{"key":"B79","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41575-020-0300-1","article-title":"Pancreatic cancer stroma: an update on therapeutic targeting strategies","volume":"17","author":"Hosein","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1055\/s-0044-101757","article-title":"ASCO- and ESMO-update 2017 - highlights of the 53. meeting of the American Society of Clinical Oncology\/ASCO 2017 and European Society for Medical Oncology\/ESMO congress 2017","volume":"56","author":"Ettrich","year":"2018","journal-title":"Z Gastroenterol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00590","article-title":"Randomized phase III trial of pegvorhyaluronidase alfa with nab-paclitaxel plus gemcitabine for patients with hyaluronan-high metastatic pancreatic adenocarcinoma","volume":"38","author":"Van Cutsem","year":"2020","journal-title":"J Clin Oncol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008431","article-title":"An oncolytic vaccinia virus encoding hyaluronidase reshapes the extracellular matrix to enhance cancer chemotherapy and immunotherapy","volume":"12","author":"Wang","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2022.05.007","article-title":"Development and characterization of human primary cholangiocarcinoma cell lines","volume":"192","author":"Isidan","year":"2022","journal-title":"Am J Pathol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2023.101279","article-title":"Matrix metalloproteinase-2 inducing COL1A1 synthesis via integrin alpha V promotes invasion and metastasis of cholangiocarcinoma cells","volume":"29","author":"Pan","year":"2024","journal-title":"Ann Hepatol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-020-0505-4","article-title":"Crenigacestat, a selective NOTCH1 inhibitor, reduces intrahepatic cholangiocarcinoma progression by blocking VEGFA\/DLL4\/MMP13 axis","volume":"27","author":"Mancarella","year":"2020","journal-title":"Cell Death Differ"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.800630","article-title":"Indoleamine 2,3-dioxygenase 1: A promising therapeutic target in Malignant tumor","volume":"12","author":"Song","year":"2021","journal-title":"Front Immunol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13045-021-01080-8","article-title":"Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy","volume":"14","author":"Tang","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.837230","article-title":"Adenosine-A2A receptor pathway in cancer immunotherapy","volume":"13","author":"Sun","year":"2022","journal-title":"Front Immunol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.ccell.2022.11.016","article-title":"Hyaluronan driven by epithelial aPKC deficiency remodels the microenvironment and creates a vulnerability in mesenchymal colorectal cancer","volume":"41","author":"Martinez-Ordonez","year":"2023","journal-title":"Cancer Cell"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006130","article-title":"Synergistic therapeutic combination with a CAF inhibitor enhances CAR-NK-mediated cytotoxicity via reduction of CAF-released IL-6","volume":"11","author":"Lee","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-024-01228-9","article-title":"Specific ECM degradation potentiates the antitumor activity of CAR-T cells in solid tumors","volume":"21","author":"Zheng","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2021.1913791","article-title":"Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy","volume":"13","author":"Waldhauer","year":"2021","journal-title":"MAbs"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1559465\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T11:00:40Z","timestamp":1739358040000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1559465\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,12]]},"references-count":92,"alternative-id":["10.3389\/fimmu.2025.1559465"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1559465","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,12]]},"article-number":"1559465"}}